Avricore Health Inc. Files January 2025 6-K Report
Ticker: AVCRF · Form: 6-K · Filed: Feb 6, 2025 · CIK: 1355736
| Field | Detail |
|---|---|
| Company | Avricore Health INC. (AVCRF) |
| Form Type | 6-K |
| Filed Date | Feb 6, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: reporting, foreign-private-issuer, company-update
Related Tickers: AVRX
TL;DR
AVRICORE HEALTH (AVRX) filed its Jan 2025 6-K. Standard foreign private issuer report.
AI Summary
Avricore Health Inc. filed a Form 6-K on February 6, 2025, for the month of January 2025. The company, formerly known as Vanc Pharmaceuticals Inc., NUVA Pharmaceuticals Inc., and ALDA Pharmaceuticals Corp., is headquartered in Vancouver, BC. This filing is a report of a foreign private issuer.
Why It Matters
This filing provides routine updates for Avricore Health Inc. as a foreign private issuer, which is important for investors tracking the company's compliance and reporting activities.
Risk Assessment
Risk Level: low — This filing is a routine report for a foreign private issuer and does not contain significant new financial or operational information that would inherently increase risk.
Key Players & Entities
- Avricore Health Inc. (company) — Registrant
- Vanc Pharmaceuticals Inc. (company) — Former company name
- NUVA Pharmaceuticals Inc. (company) — Former company name
- ALDA Pharmaceuticals Corp. (company) — Former company name
- February 6, 2025 (date) — Filing date
- January 2025 (date) — Reporting period
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose of this Form 6-K filing is to report information required by Avricore Health Inc. as a foreign private issuer for the month of January 2025.
When was this Form 6-K filed with the SEC?
This Form 6-K was filed with the SEC on February 6, 2025.
What is Avricore Health Inc.'s principal executive office address?
Avricore Health Inc.'s principal executive office is located at 1120-789 West Pender St, Vancouver, BC, V6C 1H2.
Has Avricore Health Inc. previously operated under different names?
Yes, Avricore Health Inc. has previously operated under the names Vanc Pharmaceuticals Inc., NUVA Pharmaceuticals Inc., and ALDA Pharmaceuticals Corp.
Does Avricore Health Inc. file annual reports under Form 20-F or Form 40-F?
Avricore Health Inc. files annual reports under Form 20-F.
Filing Stats: 382 words · 2 min read · ~1 pages · Grade level 17.4 · Accepted 2025-02-05 20:10:46
Filing Documents
- form6-k.htm (6-K) — 18KB
- ex99-1.htm (EX-99.1) — 32KB
- ex99-1_001.jpg (GRAPHIC) — 34KB
- 0001493152-25-005067.txt ( ) — 98KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. AVRICORE HEALTH INC. Date: February 05, 2025 By “Kiki Smith” Kiki Smith Chief Financial Officer SEC1815(04-09) Persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number